Pfizer Inc filed a lawsuit against Metsera and Novo Nordisk, accusing them of anticompetitive behavior. Novo’s surprise counter-bid for Metsera disrupted Pfizer’s $7.3 billion deal. Pfizer aims to enter the $150 billion obesity market with Metsera’s help. Novo’s proposal is seen as an attempt to eliminate a potential American rival in the GLP-1 drug market. Pfizer alleges that Metsera’s shareholders conspired with Novo. Pfizer filed a second lawsuit seeking to block the termination of the agreement. Metsera and Novo have not commented on the issue.

Read more at Yahoo Finance: Pfizer files second lawsuit against Metsera, Novo Nordisk